Oregovomab

Summary

Oregovomab (CHEMBL2107917) is a phase-3 clinical-stage antibody; indicated across 5 conditions including ovarian carcinoma and ovarian neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 5 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107917
Name	Oregovomab
Type	Antibody
Max phase	3

Also known as: Oregovomab, Oregovamab, Ovarex, mAb-B43.13, OREGOVOMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ovarian carcinoma	3	MONDO:0005140	EFO:0001075
ovarian neoplasm	3	MONDO:0021068	EFO:0003893
ovarian cancer	3	MONDO:0008170	MONDO:0008170
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE2	8
PHASE1/PHASE2	4
PHASE3	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04498117	PHASE3	ACTIVE_NOT_RECRUITING	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT00050375	PHASE3	TERMINATED	Clinical Trial for Ovarian Cancer (OvaRex®)
NCT04938583	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
NCT05335993	PHASE2	ACTIVE_NOT_RECRUITING	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
NCT05605535	PHASE2	ACTIVE_NOT_RECRUITING	Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
NCT00003634	PHASE2	UNKNOWN	Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
NCT00004064	PHASE2	UNKNOWN	Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00034138	PHASE1/PHASE2	TERMINATED	A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
NCT00034372	PHASE2	TERMINATED	Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
NCT00086632	PHASE2	TERMINATED	Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
NCT01616303	PHASE2	COMPLETED	A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
NCT01959672	PHASE2	COMPLETED	Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
NCT03100006	PHASE1/PHASE2	TERMINATED	Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
NCT04620954	PHASE1/PHASE2	UNKNOWN	Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
NCT03162562	PHASE1	TERMINATED	The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
NCT00551265	Not specified	WITHDRAWN	Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).